Enzychem Lifesciences Corporation is engaged in developing, produces, and markets active pharmaceutical ingredients (APIs) and functional health foods. The company is also developing drugs to treat chemotherapy-induced neutropenia and thrombocytopenia, sepsis, cancers, and autoimmune disorders. Its APIs primarily comprise D-Cycloserine and Terizidone that are used to treat tuberculosis; antibiotics in the family of cephalosporin, such as Cefbuperazone and Cefazedone; and other APIs for anti-coagulant and anti-inflammatory analgesic drugs. Enzychem Lifesciences Corporation exports its APIs for antibiotics and cosmetic ingredients to Japan, India, Pakistan, Russia, the CIS countries, the United Kingdom, Germany, Peru, Thailand, Taiwan, Malaysia, and other countries. The company was founded in 1999 and is headquartered in Daejeon, South Korea.
Headquarters
59, Bio valley-ro Jecheon-si Chungbuk
Jecheon; Chungcheongbuk;
Contact Details: Purchase the Enzychem Lifesciences Corporation report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service